FHL2 regulates cell cycle-dependent and doxorubicin-induced p21 Cip1/Waf1 expression in breast cancer cells

Cell Cycle

Volumn 6, Issue 14, 2007, Pages 1779-1788

  Martin, Bernd T ^a   Kleiber, Kai ^a   Wixler, Viktor ^b   Raab, Monika ^a   Zimmer, Brigitte ^a   Kaufmann, Manfred ^a   Strebhardt, Klaus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast cancer; c Jun; Cell cycle; FHL2; MAPK signaling; p21Waf1 Cip1; Transcriptional coactivator

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; LIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SHORT HAIRPIN RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOMA IN SITU; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 34548216869     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.14.4448     Document Type: Article

References (59)

1. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol 1996; 10:1167-77.
2. Michelsen JW, Schmeichel KL, Beckerle MC, Winge DR. The LIM motif defines a specific zinc-binding protein domain. Proc Natl Acad Sci USA 1993; 90:4404-8.
3. Kosa JL, Michelsen JW, Louis HA, Olsen JI, Davis DR, Beckerle MC, Winge DR. Common metal ion coordination in LIM domain proteins. Biochemistry 1994; 33:468-77.
4. Morgan MJ, Madgwick AJ. The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle. Biochem Biophys Res Commun 1999; 255:245-50.
5. Chu PH, Ruiz-Lozano P, Zhou Q, Cai C, Chen J. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev 2000; 95:259-65.
6. Tanahashi H, Tabira T. Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum Mol Genet 2000; 9:2281-9.
7. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 2000; 151:495-506.
8. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000; 19:359-69.
9. McLoughlin P, Ehler E, Carlile G, Licht JD, Schafer BW. The LIM-only protein DRAL/ FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J Biol Chem 2002; 277:37045-53.
10. Morlon A, Sassone-Corsi P. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA 2003; 100:3977-82.
11. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005; 24:1021-32.
12. Lange S, Auerbach D, McLoughlin P, Perriard E, Schafer BW, Perriard JC, Ehler E. Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 2002; 115:4925-36.
13. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D. TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation. FEBS Lett 2002; 521:165-9.
14. Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M, Sonnenberg A, Paulsson M. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem 2000; 275:33669-78.
15. Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 2002; 277:12053-60.
16. Samson T, Smyth N, Janetzky S, Wendler O, Muller JM, Schule R, von der MH, von der MK, Wixler V. The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor. J Biol Chem 2004; 279:28641-52.
17. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M, Behrens J, von der MK, Starzinski-Powitz A, Wixler V. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol 2002; 159:113-22.
18. Kleiber K, Strebhardt K, Martin BT. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 2007; 27:55-61.
19. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben Ze'ev A, Medrano EE. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003; 63:6626-34.
20. Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG, Schafer BW. Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol 1997; 16:433-42.
21. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schule R, Muller JM. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004; 24:921-7.
22. Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH, Friedman RA, Powell CA. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004; 170:167-74.
23. Gabriel B, Fischer DC, Orlowska-Volk M, zur HA, Schule R, Muller JM, Hasenburg A. Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study. J Soc Gynecol Investig 2006; 13:69-75.
24. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353:670-4.
25. Ogawa S, Lozach J, Jepsen K, Sawka-Verhelle D, Perissi V, Sasik R, Rose DW, Johnson RS, Rosenfeld MG, Glass CK. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci USA 2004; 101:14461-6.
26. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19:142-9.
27. Sabapathy K, Wagner EF. JNK2: A negative regulator of cellular proliferation. Cell Cycle 2004; 3:1520-3.
28. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20:2401-12.
29. Vogt PK. Jun, the oncoprotein. Oncogene 2001; 20:2365-77.
30. Purcell NH, Darwis D, Bueno OF, Muller JM, Schule R, Molkentin JD. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 2004; 24:1081-95.
31. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16:481-8.
32. Yan J, Zhu J, Zhong H, Lu Q, Huang C, Ye Q. BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett 2003; 553:183-9.
33. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat 2004; 83:249-89.
34. Samuel T, Weber HO, Funk JO. Linking DNA damage to cell cycle checkpoints. Cell Cycle 2002; 1:162-8.
35. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle 2004; 3:134-7.
36. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65:3980-5.
37. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2:581-91.
38. An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: The role of the NF-kappaB and JNK/AP1 pathways. Oncogene 2003; 22:3371-85.
39. Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 1999; 19:6742-53.
40. Gabriel B, Fischer DC, Orlowska-Volk M, zur HA, Schule R, Muller JM, Hasenburg A. Expression of the transcriptional coregulator FHL2 in human breast cancer: A clinicopathologic study. J Soc Gynecol Investig 2006; 13:69-75.
41. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408:429-32.
42. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344:276-85.
43. Coser KR, Chesnes J, Hur JY, Ray S, Isselbacher KJ, Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proceedings of the National Academy of Sciences of the United States of America 2003; 100:13994-9.
44. Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I, Saito I, Saruta T. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocrine Research 2004; 30:617-21.
45. Fan Y, Borowsky AD, Weiss RH. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2003; 2:773-82.
46. 2 arrest after DNA damage. Science 1998; 282:1497-501.
47. 2/M-phase transition. Mol Cell Biol 1998; 18:546-57.
48. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006; 25:7305-10.
49. Arbel-Goren R, Levy Y, Ronen D, Zick Y. Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8. J Biol Chem 2005; 280:19105-14.
50. Kobayashi K, Tsukamoto I. Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21(WAF1/CIP1) preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochim Biophys Acta 2001; 1537:79-88.
51. Blagosklonny MV. Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle 2002; 1:391-3.
52. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000; 7:721-8.
53. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): Association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002; 179:1-14.
54. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002; 277:11352-61.
55. Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, Hugh TB, Henshall SM, Sutherland RL. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61:8830-7.
56. Weiss RH, Marshall D, Howard L, Corbacho AM, Cheung AT, Sawai ET. Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1/ Cip1). Cancer Lett 2003; 189:39-48.
57. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001; 158:639-46.
58. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22:256-65.
59. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF, Wong BC. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132:1066-76.